These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 8632409)
21. Novel (R)-2-amino-5-fluorotetralins: dopaminergic antagonists and inverse agonists. Malmberg A; Höök BB; Johansson AM; Hacksell U J Med Chem; 1996 Oct; 39(22):4421-9. PubMed ID: 8893836 [TBL] [Abstract][Full Text] [Related]
22. 'Click' D(1) receptor agonists with a 5-HT(1A) receptor pharmacophore producing D(2) receptor activity. Zhang J; Zhang H; Cai W; Yu L; Zhen X; Zhang A Bioorg Med Chem; 2009 Jul; 17(14):4873-80. PubMed ID: 19559623 [TBL] [Abstract][Full Text] [Related]
23. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors. Campiani G; Butini S; Trotta F; Fattorusso C; Catalanotti B; Aiello F; Gemma S; Nacci V; Novellino E; Stark JA; Cagnotto A; Fumagalli E; Carnovali F; Cervo L; Mennini T J Med Chem; 2003 Aug; 46(18):3822-39. PubMed ID: 12930145 [TBL] [Abstract][Full Text] [Related]
24. Prediction of drug-induced catalepsy based on dopamine D1, D2, and muscarinic acetylcholine receptor occupancies. Haraguchi K; Ito K; Kotaki H; Sawada Y; Iga T Drug Metab Dispos; 1997 Jun; 25(6):675-84. PubMed ID: 9193868 [TBL] [Abstract][Full Text] [Related]
25. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. Lewis MM; Watts VJ; Lawler CP; Nichols DE; Mailman RB J Pharmacol Exp Ther; 1998 Jul; 286(1):345-53. PubMed ID: 9655879 [TBL] [Abstract][Full Text] [Related]
26. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies. Hou T; Zhu L; Chen L; Xu X J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563 [TBL] [Abstract][Full Text] [Related]
27. Persistent activation of the dopamine D1 receptor contributes to prolonged receptor desensitization: studies with A-77636. Lin CW; Bianchi BR; Miller TR; Stashko MA; Wang SS; Curzon P; Bednarz L; Asin KE; Britton DR J Pharmacol Exp Ther; 1996 Mar; 276(3):1022-9. PubMed ID: 8786531 [TBL] [Abstract][Full Text] [Related]
28. D2S, D2L, D3, and D4 dopamine receptors couple to a voltage-dependent potassium current in N18TG2 x mesencephalon hybrid cell (MES-23.5) via distinct G proteins. Liu LX; Burgess LH; Gonzalez AM; Sibley DR; Chiodo LA Synapse; 1999 Feb; 31(2):108-18. PubMed ID: 10024007 [TBL] [Abstract][Full Text] [Related]
29. Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation. Wersinger C; Chen J; Sidhu A Mol Cell Neurosci; 2004 Jan; 25(1):124-37. PubMed ID: 14962746 [TBL] [Abstract][Full Text] [Related]
30. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents. Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553 [TBL] [Abstract][Full Text] [Related]
31. N-(omega-(4-(2-methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as dopamine D2 and D3 receptor ligands. Hackling A; Ghosh R; Perachon S; Mann A; Höltje HD; Wermuth CG; Schwartz JC; Sippl W; Sokoloff P; Stark H J Med Chem; 2003 Aug; 46(18):3883-99. PubMed ID: 12930150 [TBL] [Abstract][Full Text] [Related]
32. Perinatal asphyxia induces long-term changes in dopamine D1, D2, and D3 receptor binding in the rat brain. Chen Y; Hillefors-Berglund M; Herrera-Marschitz M; Bjelke B; Gross J; Andersson K; von Euler G Exp Neurol; 1997 Jul; 146(1):74-80. PubMed ID: 9225740 [TBL] [Abstract][Full Text] [Related]
33. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents. Campiani G; Butini S; Fattorusso C; Catalanotti B; Gemma S; Nacci V; Morelli E; Cagnotto A; Mereghetti I; Mennini T; Carli M; Minetti P; Di Cesare MA; Mastroianni D; Scafetta N; Galletti B; Stasi MA; Castorina M; Pacifici L; Vertechy M; Di Serio S; Ghirardi O; Tinti O; Carminati P J Med Chem; 2004 Jan; 47(1):143-57. PubMed ID: 14695828 [TBL] [Abstract][Full Text] [Related]
35. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor. Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168 [TBL] [Abstract][Full Text] [Related]
36. Affinity for dopamine D2, D3, and D4 receptors of 2-aminotetralins. Relevance of D2 agonist binding for determination of receptor subtype selectivity. van Vliet LA; Tepper PG; Dijkstra D; Damsma G; Wikström H; Pugsley TA; Akunne HC; Heffner TG; Glase SA; Wise LD J Med Chem; 1996 Oct; 39(21):4233-7. PubMed ID: 8863800 [TBL] [Abstract][Full Text] [Related]
37. CoMFA study of novel phenyl ring-substituted 3alpha-(diphenylmethoxy)tropane analogues at the dopamine transporter. Newman AH; Izenwasser S; Robarge MJ; Kline RH J Med Chem; 1999 Sep; 42(18):3502-9. PubMed ID: 10479283 [TBL] [Abstract][Full Text] [Related]
38. Dopamine D1 receptor ligands: where are we now and where are we going. Zhang J; Xiong B; Zhen X; Zhang A Med Res Rev; 2009 Mar; 29(2):272-94. PubMed ID: 18642350 [TBL] [Abstract][Full Text] [Related]
39. A 3D QSAR study on a set of dopamine D4 receptor antagonists. Boström J; Böhm M; Gundertofte K; Klebe G J Chem Inf Comput Sci; 2003; 43(3):1020-7. PubMed ID: 12767161 [TBL] [Abstract][Full Text] [Related]